Silmitasertib

Synopsis, Chemistry

DEVELOPMENTS

21 Drug(s) in Development

21 Drug(s) in Development

DIGITAL CONTENT

23 News

23 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 1009820-21-6, Cx-4945, 5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid, Cx4945, Cx 4945, Cx-4945 (silmitasertib)

Molecular Formula

C₁₉H₁₂ClN₃O₂

Molecular Weight

349.8 g/mol

InChI Key

MUOKSQABCJCOPU-UHFFFAOYSA-N

FDA UNII

C6RWP0N0L2

Silmitasertib is an orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm.

1 2D Structure

Silmitasertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid

2.1.2 InChI

InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)

2.1.3 InChI Key

MUOKSQABCJCOPU-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4

2.2 Other Identifiers

2.2.1 UNII

C6RWP0N0L2

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid

2. Cx 4945

3. Cx-4945

4. Cx4945

2.3.2 Depositor-Supplied Synonyms

1. 1009820-21-6

2. Cx-4945

3. 5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic Acid

4. Cx4945

5. Cx 4945

6. Cx-4945 (silmitasertib)

7. Silmitasertib [inn]

8. Cx4945 (silmitasertib)

9. 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid

10. 5-[(3-chlorophenyl)amino]-benzo[c]-2,6-naphthyridine-8-carboxylic Acid

11. Cx-4945 Free Acid

12. C6rwp0n0l2

13. Silmitasertib (cx-4945)

14. Chembl1230165

15. 5-((3-chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic Acid

16. 5-[(3-chlorophenyl)amino]benzo[c]2,6-naphthyridine-8-carboxylic Acid

17. 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic Acid

18. 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid

19. Unii-c6rwp0n0l2

20. Benzo[c]-2,6-naphthyridine-8-carboxylic Acid, 5-[(3-chlorophenyl)amino]-

21. 5-((3-chlorophenyl)amino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid

22. Benzo(c)-2,6-naphthyridine-8-carboxylic Acid, 5-((3-chlorophenyl)amino)-

23. 3ng

24. 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic Acid

25. Silmitasertib; Cx 4945

26. Cx-4945 (silmitaserib)

27. Cx 4945 (silmitasertib)

28. Cx-4945 - Silmitasertib

29. Schembl629082

30. Silmitasertib [who-dd]

31. Gtpl8126

32. Dtxsid40143602

33. Ex-a070

34. Hms3244m13

35. Hms3244m14

36. Hms3244n13

37. Hms3655f16

38. Hms3746e13

39. Bcp02399

40. Bdbm50335638

41. Mfcd13184796

42. Nsc761193

43. Nsc800885

44. S2248

45. Zinc58638454

46. 5-[(3-chlorophenyl)amino]benzo[c]-2,6-naphthyridine-8-carboxylic Acid

47. Akos005266722

48. Bcp9000560

49. Ccg-264955

50. Cs-0563

51. Db15408

52. Ex-8673

53. Nsc-761193

54. Nsc-800885

55. Sb17201

56. Ncgc00263192-01

57. Ncgc00263192-02

58. Ncgc00263192-09

59. Ac-28426

60. As-16253

61. Hy-50855

62. Db-016103

63. Ft-0723994

64. Sw218157-2

65. A25034

66. J-000296

67. J-516169

68. W-204393

69. Cx-4945,cas:1009820-21-6

70. Q27076934

71. 5-[(3-chlorophenyl)amino]pyrido[4,3-c]quinoline-8-carboxylic Acid

2.4 Create Date

2008-03-17

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₂ClN₃O₂
Molecular Weight	349.8 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	3
Exact Mass	349.0618043 g/mol
Monoisotopic Mass	349.0618043 g/mol
Topological Polar Surface Area	75.1 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	491
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1